Nanobiotix S.A. (NASDAQ:NBTX – Get Rating) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 1,000 shares, a drop of 44.4% from the April 30th total of 1,800 shares. Based on an average daily volume of 1,600 shares, the days-to-cover ratio is presently 0.6 days.
Separately, Zacks Investment Research raised Nanobiotix from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Saturday.
NBTX stock traded up $0.31 during trading on Friday, reaching $5.32. 113 shares of the company were exchanged, compared to its average volume of 4,988. The company has a 50-day moving average of $6.28 and a two-hundred day moving average of $7.49. Nanobiotix has a twelve month low of $4.65 and a twelve month high of $18.00.
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Nanobiotix (NBTX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.